Han JE, Yi SK, Wang S, et al. – Because findings from previous trials on neoadjuvant chemotherapy (NAC) in endemic regions of nasopharyngeal carcinoma (NPC) demonstrated improved survival–yet there remains a paucity of data with respect to nonendemic regions—researchers ascertained if adding NAC to concurrent chemoradiation improves overall survival (OS), particularly in high-risk nonendemic patients. Definitively treated NPC patients (n = 5,424) from the National Cancer Database were examined for predictors of NAC and NAC effects on OS via multivariate Cox proportional hazards analysis. Researchers found evidence to suggest that NAC may boost OS in patients with nonendemic NPC at higher risk of distant micrometastases, especially N3 disease and those with unfavorable histology.